Effective Pain Control With Very Low Dose Palliative Radiation Therapy for Patients With Multiple Myeloma With Uncomplicated Osseous Lesions.
Journal
Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247
Informations de publication
Date de publication:
Historique:
received:
09
07
2020
revised:
08
02
2021
accepted:
14
05
2021
entrez:
14
7
2021
pubmed:
15
7
2021
medline:
15
7
2021
Statut:
epublish
Résumé
Osteolytic lesions are present in 75% of patients with multiple myeloma (MM) and frequently require palliation with radiation therapy (RT). Prior case series of patients with MM with bone pain undergoing palliative RT suggests doses ≥12 Gy (equivalent dose in 2Gy fractions, EQD2) provide excellent bone pain relief. However, recent advances in care and novel biologic agents have significantly improved overall survival and quality of life for patients with MM. We hypothesized that lower-dose RT (LDRT, EQD2 <12 Gy) offers an effective alternative to higher-dose RT (HDRT, EQD2 ≥12 Gy) for palliation of painful, uncomplicated MM bone lesions. We retrospectively identified patients with MM treated with RT for uncomplicated, painful bone lesions and stratified by EQD2 ≥/< 12 Gy. Clinical pain response (CPR) rates, acute and late toxicity, pain response duration, and retreatment rates between LDRT and HDRT groups were analyzed. Thirty-five patients with 70 treated lesions were included: 24 patients (48 lesions) treated with HDRT and 11 patients (22 lesions) with LDRT. Median follow-up was 14 and 16.89 months for HDRT and LDRT, respectively. The median dose of HDRT treatment was 20 Gy versus 4 Gy in the LDRT group. The CPR rate was 98% for HDRT and 95% for LDRT. There was no significant difference in any-grade acute toxicity between the HDRT and LDRT cohorts (24.5% vs 9.1%, Χ In this study, LDRT effectively palliated painful, uncomplicated MM bony lesions with acceptable CPR and duration of palliation. These data support prospective comparisons of LDRT versus HDRT for palliation of painful, uncomplicated MM bony lesions.
Sections du résumé
BACKGROUND
BACKGROUND
Osteolytic lesions are present in 75% of patients with multiple myeloma (MM) and frequently require palliation with radiation therapy (RT). Prior case series of patients with MM with bone pain undergoing palliative RT suggests doses ≥12 Gy (equivalent dose in 2Gy fractions, EQD2) provide excellent bone pain relief. However, recent advances in care and novel biologic agents have significantly improved overall survival and quality of life for patients with MM. We hypothesized that lower-dose RT (LDRT, EQD2 <12 Gy) offers an effective alternative to higher-dose RT (HDRT, EQD2 ≥12 Gy) for palliation of painful, uncomplicated MM bone lesions.
METHODS
METHODS
We retrospectively identified patients with MM treated with RT for uncomplicated, painful bone lesions and stratified by EQD2 ≥/< 12 Gy. Clinical pain response (CPR) rates, acute and late toxicity, pain response duration, and retreatment rates between LDRT and HDRT groups were analyzed.
RESULTS
RESULTS
Thirty-five patients with 70 treated lesions were included: 24 patients (48 lesions) treated with HDRT and 11 patients (22 lesions) with LDRT. Median follow-up was 14 and 16.89 months for HDRT and LDRT, respectively. The median dose of HDRT treatment was 20 Gy versus 4 Gy in the LDRT group. The CPR rate was 98% for HDRT and 95% for LDRT. There was no significant difference in any-grade acute toxicity between the HDRT and LDRT cohorts (24.5% vs 9.1%, Χ
CONCLUSION
CONCLUSIONS
In this study, LDRT effectively palliated painful, uncomplicated MM bony lesions with acceptable CPR and duration of palliation. These data support prospective comparisons of LDRT versus HDRT for palliation of painful, uncomplicated MM bony lesions.
Identifiants
pubmed: 34258474
doi: 10.1016/j.adro.2021.100729
pii: S2452-1094(21)00087-7
pmc: PMC8256178
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100729Informations de copyright
© 2021 The Author(s).
Références
Blood. 1989 May 1;73(6):1677-81
pubmed: 2713500
Radiat Oncol J. 2016 Mar;34(1):59-63
pubmed: 27104168
Lancet Oncol. 2014 Feb;15(2):164-71
pubmed: 24369114
Pract Radiat Oncol. 2019 Jul - Aug;9(4):e400-e406
pubmed: 30802617
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):480-4
pubmed: 25176474
Strahlenther Onkol. 2017 Sep;193(9):742-749
pubmed: 28573476
Adv Radiat Oncol. 2018 Sep 27;4(1):112-117
pubmed: 30706018
Leukemia. 2014 May;28(5):1122-8
pubmed: 24157580
J Clin Oncol. 2014 Sep 10;32(26):2913-9
pubmed: 25113773
Arch Intern Med. 2000 Nov 27;160(21):3252-7
pubmed: 11088086
Radiat Oncol. 2015 Mar 28;10:71
pubmed: 25889851
Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1452-7
pubmed: 16413695
Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):794-808
pubmed: 29976492
Haematologica. 2020 Jul;105(7):e355-e357
pubmed: 31919088
Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):801-4
pubmed: 7683017